LTR Pharma Limited

As of June 30, 2025, LTR Pharma Limited carries a market capitalization of 52.48M, placing it among publicly traded companies globally. Its enterprise value stands at 20.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2025, LTR Pharma Limited has 180.98M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 332.71, and the price-to-book ratio stands at 1.67.

These figures are as of June 30, 2025. The EV/Sales ratio of 141.82 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 20.68M versus a market cap of 52.48M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, LTR Pharma Limited maintains a current ratio of 45.78, meaning it holds 45.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, LTR Pharma Limited posted a negative return on equity (ROE) of -32.47, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.44, reflecting losses generated across the asset base.

As of the close on October 22, 2026, LTR Pharma Limited's stock has declined approximately 9.43% over the past 52 weeks. The 50-day moving average sits at 0.48, while the 200-day moving average is 0.48.

Over the twelve months ended June 30, 2025, LTR Pharma Limited generated 145,779.00 in revenue and converted that into -5.59M in net income, yielding earnings per share of -0.03. EBITDA reached -7.47M, while operating income came in at -7.47M.

These figures are as of June 30, 2025. Total book value stands at 31.51M, with working capital of 31.37M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

These figures cover the twelve months ended June 30, 2025. The operating margin of -5,123.89 and net profit margin of -3,837.01 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -63.58, meaning LTR Pharma Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2025, LTR Pharma Limited has an Altman Z-Score of 44.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.